Oxycodone is partly metabolized to the active metabolite oxymorphone by hepatic CYP2D6 in the liver. Significant genetic variability in CYP2D6 activity affects oxymorphone formation. This study aimed to associate CYP2D6 genotype and oxycodone's metabolism. Methods: 30 children were administered oral oxycodone postoperatively. Plasma levels of oxycodone and oxymorphone, and CYP2D6 genotype were analyzed. CYP2D6 genotype and oxycodone metabolism phenotype were determined based on CYP2D6 total activity score (TAS) and metabolism phenotype: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM) or ultrarapid metabolizer (UM). Results: Compared with PM/IM subjects, significantly greater oxymorphone exposure was seen in EM subjects (p = 0.02 for C max , p = 0.016 for AUC 0-6 and p = 0.026 for AUC 0-24 ). Similarly, higher TAS value was found to be associated with greater oxymorphone exposure. Higher conversion of oxycodone to oxymorphone was observed in EM subjects compared with PM/IM subjects (p = 0.0007 for C max , p = 0.001 for AUC 0-6 and p = 0.004 for AUC 0-24 ). Conclusion: CYP2D6 phenotypes explain metabolism of oxycodone in children, and oxymorphone exposure is higher in CYP2D6 EM phenotype. Further studies are needed to predict the occurrence of adverse event and tailor oxycodone dose for a specific CYP2D6 phenotype.
Pain management in pediatric surgical patients is complicated due to the risk of adverse effects of analgesics and inadequate anesthesia [1, 2] . In the USA, approximately 6 million children undergo painful surgeries each year. Opioids are some of the most effective analgesics available and are considered foundational in clinical pain management [3] . Despite this efficacy, adverse events such as respiratory depression and death have been attributed to opioid administration in children [4] . For many years, codeine was thought to be optimum analgesic for children due to oral administration, wide thera peutic index and low probability of respiratory depression, but variable metabolism and concerns on its contribution to these untoward events have caused a critical re-evaluation of this drug's use in the pediatric population [5] .
Codeine is an opioid prodrug that is transformed to the active metabolite, morphine, by P-450 enzyme CYP2D6. In CYP2D6 poor metabolizer (PM), codeine is minimally converted to morphine, while in CYP2D6 ultra-rapid metabolizer (UM), very high concentrations of morphine are generated [6] . The variation in pharmacokinetics due to underlying pharmacogenetics results in varying drug effects, ranging from ineffective to toxic [7] . In February 2013, the US FDA issued its strongest warning against the use of codeine in children undergoing tonsillectomy CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients due to reports of deaths and anoxic injuries related to CYP2D6 genetic variations and concomitant variable codeine metabolism [8] . In CYP2D6 UM, excess morphine generation and adverse toxic effects are observed after codeine administration [6] . The FDA and other health organizations, such as WHO and EMA are considering a declaration of contraindication for codeine use in children [9] . Additionally, there is evidence that some nursing mothers are UMs of codeine which has led to unpredictable levels of morphine in breast milk and infant death [10] . Hence, there is a need to find a safer alternative to codeine in children. Oxycodone is another commonly used but more restricted opioid administered for acute and chronic pain [11] . A μ-opioid receptor agonist, oxycodone is semisynthetic in nature [12] and has 60-80% bioavailability upon oral administration [13, 14] . Though it has been in use for over 100 years, minimal information is available regarding the pharmacokinetics and pharmaco dynamics of oxycodone in the pediatric population. Oxycodone is metabolized by CYP2D6 to oxymorphone and CYP3A4 to noroxycodone, a metabolite with poor antinociceptive effect [15] . Oxymorphone has 40-times more affinity for μ-opioid receptor and is 14-times more potent than oxycodone in efficacy [16] . Both noroxycodone and oxymorphone are further metabolized to noroxymorphone, which has three-times and ten-times higher affinity for μ-opioid receptor in comparison to oxycodone and noroxycodone, respectively [13] . Since oxycodone, like codeine, is partly metabolized by polymorphic CYP2D6 to an active metabolite, it is expected to have excessive adverse effects in CYP2D6 UMs (Figure 1 ). In fact, oxycodone has recently been shown not to be a safe alternative to codeine for infants of nursing mothers [17] . In CYP2D6 PM, poor analgesic effect was observed following oxycodone administration [18] . Two case studies, first involving 64 healthy adults with three CYP2D6 UM individuals and other involving a CYP2D6 PM patient, have reported variation in oxycodone pharmacology due to variation in CYP2D6 genotype [19, 20] . A better understanding of the genetic influence of CYP2D6 on the pharmacokinetics of oxycodone could help clarify the role of genetic variability in the safety of children taking oxycodone especially in unmonitored home setting following surgery.
To this end, we hypothesized that genetic variations of CYP2D6 alleles can alter the pharmacokinetics of oxycodone and its metabolites. The aim of this prospective observational study was to determine the impact of genetic polymorphism of CYP2D6 on oxyco done pharmacokinetics and clearance in children taking oxycodone following painful surgery.
Methods

Study design
We conducted a prospective observational study that is part of an ongoing Phase IV study to characterize the pharmacokinetics and to evaluate the safety of oxycodone administered to children following a surgical procedure. Approval was obtained from the Cincinnati Children's Hospital Medical Center Institutional Review Board. Written informed consent was obtained from parents/legal guardians. This study is registered with ClinicalTrials.gov, identifier #NCT01959204.
Participants
Children aged 2-17 years undergoing painful orthopedic, thoracic, urology and colorectal procedures were enrolled as part of the larger study. Subjects of American Society of Anesthesiologists status I or II were either enrolled preoperatively or post operatively with the expectation that they would require IV access Age (year) and bodyweight (kg) of subjects are presented as mean ± standard deviation for all subjects as well as subjects categorized in groups based on age. Genetic factors contributing to oxycodone & its metabolites in children Research Article after inpatient surgery and postoperative analgesia with an opiate-level medication. Children were excluded if they were known to have used an inhibitor or inducer of CYP3A4 within 14 days of dosing with oxycodone [21] . Children were excluded if they had a history of smoking, alcohol consumption or drug addiction.
Patients were given oxycodone oral solution (0.1 mg/kg for children aged 2-6 years, 0.08 mg/kg for ages 7-12 years and 0.07 mg/kg for ages 13-17 years) after being postoperatively cleared to transition to oral pain medication. Safety was assessed for 24 h following oxycodone dose by monitoring and recording adverse events, vital sign measurements and physical examination findings.
Pharmacokinetic sampling
Serial blood samples for pharmacokinetic analysis were collected for the determination of plasma concentrations of oxycodone at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 h following oxycodone administration. Oxycodone and oxymorphone levels in plasma were analyzed by LC-MS/MS (Biologistic Services, CO, USA). The assay's lower limit of quantitation for oxycodone and oxymorphone was 0.02 ng/ml.
Pharmacokinetic analysis
Oxycodone and oxymorphone pharmacokinetics after a single dose of oxycodone oral solution were characterized using noncompartmental analysis using Phoenix Win-Nonlin ® (version 6.1, Pharsight, CA, USA). The peak concentration (C max ), time to peak concentration (T max ), terminal half-life (T 1/2 ) and area under the curve (AUC) were calculated for oxycodone and oxymorphone using the plasma concentration-time profiles. Actual postdose sample collection times were utilized to generate individual concentration-time profiles using noncompartmental analysis. Terminal half-lives were typically calculated using the terminal 2-3 time points after carefully examining The observed CYP2D6 alleles, phenotype, Total Activity Score (TAS), and number of subjects with specific alleles are included in the individual concentration time profile. The area under the plasma concentration time curve was calculated by the linear up/log down method. In addition to the observed AUC 0-last , partial areas under the concentration-time curves were evaluated to calculate the exposure up to 6 h (AUC 0-6 ), 12 h (AUC 0-12 ) and 24 h (AUC 0-24 ). All pharmacokinetic parameters were normalized by the actual oxycodone dose for standardization.
Genotyping
Blood was drawn in the operating room upon placement of intravenous line prior to surgery. DNA was isolated on the same day and frozen at -20°C. Batched genotyping for a panel of CYP2D6 alleles was performed in a Clinical Laboratory Improvement Amendments approved and Certification Authorization Professional-certified laboratory after clinical data were entered on study participants. CYP2D6 Genetic factors contributing to oxycodone & its metabolites in children Research Article alleles, as defined in the internationally recognized human CYP450 database [22] Predicted oxycodone metabolism phenotypes were designated by two methods: a total activity score (TAS) [24] and the descriptive metabolism phenotype (Table 2 ). The summed TAS of 1.0 represents both full function + null function alleles and reduced function + reduced function alleles which may represent two distinctive pharmacokinetic groups. Evidence exists not only for reduced expression [22, 25] but also for substrate specificity of reduced function CYP2D6 alleles [26] . Our second method using descriptive metabolism phenotype distinguishes between predicted phenotypes that contain at least one full function allele and those that do not.
Pharmacogenetic analysis
The pharmacokinetic parameters such as dosenormalized C max , AUC 0-6 , AUC 0-24 were plotted with respect to CYP2D6 genotype groups PM/IM or EM.
To establish relationship among dose-normalized C max , AUC 0-6 , and AUC 0-24 of oxycodone and oxymorphone with TAS, these parameters were plotted with respect to TAS of 0.5, 1, 1.5 and 2. Extent of conversion of oxycodone to oxymorphone with respect to CYP2D6 genotype group PM/IM or EM was investigated by plotting oxymorphone/oxycodone ratio of C max , AUC 0-6 , AUC 0-24 with respect to CYP2D6 genotype. Similarly, oxymorphone/oxycodone ratio of C max , AUC 0-6 , AUC 0-24 was compared with distinct pharmacokinetic groups formed by TAS.
Statistical analysis
Numerical data were presented as mean ± standard deviation. The statistical difference of pharmaco kinetic Genetic factors contributing to oxycodone & its metabolites in children Research Article parameter in two groups was calculated by performing nonparametric unpaired Mann-Whitney test using GraphPad software ® (GraphPad Prism, CA, USA). The p-value of less than 0.05 was considered statistically significant.
Results
Demograp.hics
A total of 30 children between ages 2 and 17 years from three different study sites were enrolled in the study after being postoperatively cleared for oral pain medication. Demographic details for all subjects and grouped as per age are presented in Table 1 . The remaining 16 children were classified as extensive metabolizers (EMs), with *1/ *1 (n = 5) and *1 / *2A (n = 6) being the most frequent genotypes.
Distribution of genotypes & phenotypes
Oxycodone & metabolite pharmacokinetics and modeling
The concentration-time profiles for oxycodone ap pear ed to have a single phase post-C max (Figure 2A ).
Oral absorption of oxycodone typically resulted in 1-2 concentration peaks with a median peak time of about 2 h with no noticeable difference across the three age groups. While fast absorption was observed in most of the subjects, delayed absorption was observed in a few subjects with peak concentrations occurring about 12 h postdosing. Overall, concentration-time profiles of oxymorphone were parallel to the observed oxycodone concentration with oxymorphone concentrations between 1 and 5% of the observed oxycodone concentration. None of the 24 h samples had observable oxymorphone concentrations ( Figure 2B ). Times to peak concentration for oxymorphone were very similar to that of oxycodone. The mean terminal half-life for oxycodone was 2.7 (±0.7) h and that for oxymorphone was 3.6 (±1.9) h. Dose-normalized C max of 2.2 (±1.5) arbitrary unit (AU) was observed for oxycodone while it was estimated to be 0.054 (±0.056) AU for oxymorphone. The dose-normalized AUC 0-24 was estimated to be 10.9 (±4.5) AU for oxycodone and 0.22 (±0.14) AU for oxymorphone.
Genetic association: impact of CYP2D6 genetic polymorphism
The impact of CYP2D6 genetic polymorphism on the oxycodone pharmacokinetics was evaluated by observing the variation of exposure markers (C max , AUC 0-6 and AUC 0-24 ) with respect to the CYP2D6 genotype and CYP2D6 TAS. There was no significant differ- ence in exposure markers of oxycodone metabolism among PM/IM and EM of CYP2D6 ( Figure 3A for dose-normalized C max , Figure 4A for dose-normalized AUC 0-6 and Figure 5A for dose-normalized AUC 0-24 ). A similar comparison of oxymorphone exposure among PM/IM and EM showed significantly higher exposure in EM. The p-value of 0.028 was observed for dose-normalized C max levels ( Figure 3A ) in PM/IM and EM. Higher dose-normalized AUC 0-6 (p = 0.0162; Figure 4A ) and dose-normalized AUC 0-24 (p = 0.026; Figure 5A ) for oxymorphone were seen in EM. As shown in Figure 5B , TAS had clear impact on dosenormalized oxymorphone AUC 0-24 (p = 0.0091 among TAS 1 and 2 groups), though a similar impact on dosenormalized oxycodone AUC 0-24 was not observed. This is consistent with the current understanding that oxymorphone formation accounts for about 1-5% of oxycodone elimination. Dose-normalized oxymorphone AUC 0-24 estimates tended to be unreliable because extrapolation after the last dose accounted for >20% of the sample. Similar results were obtained when the impact of TAS on dose-normalized AUC 0-6 ( Figure 4B ) and C max ( Figure 3B ) of oxymorphone was evaluated. IMs consistently had lower oxymorphone exposures than EMs as determined by the Mann-Whitney test. The impact of CYP2D6 activity was further evaluated using the ratio of oxymorphone-to-oxycodone exposures to normalize the impact of intersubject variation in exposure due to variable bioavailability.
Significantly higher oxymorphone/oxycodone ratio was observed for EM for C max (p = 0.0007; Figure 6A ), AUC 0-6 (p = 0.001; Figure 7A ) and AUC 0-24 (p = 0.004; Figure 8A ). As observed previously, the oxymorphone exposure relative to oxycodone exposure was consistently dependent on the CYP2D6 phenotype with higher activity phenotypes having higher oxymorphone exposures ( Figures 6B, 7B & 8B ).
Discussion
Our study offers early evidence that CYP2D6 phenotype significantly affects oxycodone metabolism in pediatric surgical patients. Patients with more active CYP2D6 activity and oxycodone metabolism had higher levels of oxymorphone in comparison to phenotypes with less CYP2D6 activity.
In an age where personalized medicine is gaining more popularity, there is increasing focus to better understand the pharmacogenetic influence on the response and side effects of opioid medications [27] [28] [29] [30] . To this end, the main purpose of this study was to identify the role of pharmacogenetic variability on the pharmacokinetics of oral oxycodone in children undergoing surgery. We have demonstrated that pheno typic activity of CYP2D6 significantly influenced oxymorphone levels in children taking oxycodone. By normalizing the impact of intersubject variation in exposure due to variable bioavailability of oxycodone, we again showed that oxymorphone exposure was higher with [31] .
Certain populations have higher prevalence of CYP2D6 UM phenotype (20% in Saudi Arabians [32] and 29% in Ethiopians [33] ) compared with 1-7% prevalence in Caucasians [19] . These individuals are likely at higher risk of toxicity from opioids metabolized by CYP2D6 pathway including oxycodone, codeine, tramadol and hydrocodone, and more vigilance is required when these opioids are administered in these population and CYP2D6 UMs.
This study included children of different age ranging from 2 to 16 year. Initially, we recruited older children (>6 years). We are trying to recruit younger children (2-6 years) in a larger study. The fractional CYP2D6 expression at birth is 3.6% of adult value and 50% adult level expression is reached at 1.2 months [34] . Thus, our findings correlating CYP2D6 phenotype with oxycodone dosing could be extrapolated for young children and even neonates. However, we need to validate our findings from older children in younger children.
In a cross-sectional study in adult cancer patients taking oxycodone, it was observed that while different CYP2D6 genotypes resulted in varying pharmacokinetics of oxycodone, they did not produce any observable difference in markers of efficacy such as pain score, symptoms of nausea, sedation and cognitive failure [35] . This adult study had many confounders and limitations in terms of robust clinical phenotypes. In another study, in healthy adult volunteers by Zwisler et al., significant difference was observed in pain reduction, pain tolerance, discomfort and oxymorphone/oxycodone ratio between CYP2D6 EM and PM individuals [36] . This study further corroborates our oxycodone PK and CYP2D6 association findings in children. This study is clinically important as children tend to experience more adverse effects including deaths and life-threatening respiratory depression from clinical use of opioids compared with adults [4] . In this study, we focused on clinical doses of oxycodone and CYP2D6 genotype on oxycodone's metabolism in children for the first time.
Recent Clinical Pharmacogenetics Implementation Consortium guidelines [37] , cautions against the use of codeine, tramadol, hydrocodone and oxycodone in CYP2D6 PMs for analgesic efficacy reasons and in UM for toxicity reasons. Further studies are needed to verify if difference in oxycodone pharmacokinetics in children results in varying postoperative response.
One limitation to our pilot study is the small number of extreme CYP2D6 phenotypes studied, which lead to fewer numbers of phenotypes in our study population. Only one child was classified as a PM and no children were identified as UMs. More patients are future science group Research Article Balyan, Mecoli, Venkatasubramanian et al. required to better understand the effect of low and ultra-rapid activity CYP2D6 phenotypes on oxycodone pharmacokinetics. It is an ongoing study and we will have a bigger sample with more PMs and UMs at the end of the study to associate not only with oxycodone's pharmaco kinetics but also with clinical outcomes. Another limitation is that we were not able to perform a direct prospective comparison of clinical effects of oxycodone with codeine. In our institution, we have stopped the use of codeine in children following tonsillectomy and other surgery after the FDA's black box warning on codeine's use in the same because of its unpredictability and number of postoperative deaths and anoxic brain injuries.
More studies are warranted to investigate whether the incidence of adverse events in children taking oxyco done is influenced by the genetic impact on oxycodone metabolism. This will help in determining the safety profile of this opioid medication in children following painful surgery. Additionally, it may allow us to better tailor pain management strategies for individual children by optimizing pain relief while avoiding adverse reactions.
Conclusion & future perspective
In conclusion, our pediatric pharmacokinetic and pharmacogenetic association pilot study shows that CYP2D6 genotypes play a significant role in the pharmaco kinetics of oxycodone and its metabolite, oxymorphone. Specifically, children identified as being EMs of oxycodone had greater exposure to oxymorphone, an active and potent metabolite of oxycodone compared with PMs.
Pharmacokinetic variations due to multiple phenotypes of CYP2D6 need to be considered when personalizing oxycodone use in a specific child. Based on CYP2D6 phenotype, a patient might need oxycodone dose adjustment or even a different therapeutic alternative not metabolized by CYP2D6 such as oral morphine, hydromorphone and tapentadol. Large studies are warranted to further ascertain whether the influence of pharmacogenetic variability on oxycodone pharmacokinetics is associated with clinically important outcomes in children. Personalized opioid selection and oxycodone dosing based on CYP2D6 genotype for an individual child may improve pain control following surgery while limiting dangerous adverse side effects.
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Executive summary
• Interindividual variation in oxycodone pharmacokinetics and generation of active metabolite oxymorphone in children is dependent upon hepatic CYP2D6 phenotype.
• Significantly higher exposure of dose-normalized oxymorphone C max (p = 0.02); AUC 0-6 (p = 0.016) and AUC (p = 0.026) was observed in extensive metabolizer phenotype, compared with poor/intermediate metabolizer phenotype.
• Greater total activity score value is associated with greater oxymorphone exposure in plasma (p = 0.009).
• Similarly, higher oxymorphone/oxycodone ratio observed for extensive metabolizer for C max (p = 0.0007); AUC 0-6 (p = 0.001) and AUC 0-24 (p = 0.004) ruling out the contribution of bioavailability in variation in findings.
• Further studies needed to ascertain impact of CYP2D6 phenotype on oxycodone pharmacodymanics in children and to tailor opioid selection and dosing in clinical setting.
